SuperworthZoetis EPS ZTS
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- $6.07
- Latest quarter, Q2 FY26
- $1.65
- +1% on a year earlier
- Fiscal year 2025
- $5.97
- +9% on the year before
Zoetis' earnings per share was $6.07 over the twelve months to Jun 30, 2026, up 5% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.65, up 1% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 12% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $5.97 | +9% |
| FY2024 | $5.47 | +8% |
| FY2023 | $5.07 | +13% |
| FY2022 | $4.50 | +5% |
| FY2021 | $4.27 | +25% |
| FY2020 | $3.42 | +10% |
| FY2019 | $3.12 | +6% |
| FY2018 | $2.93 | +67% |
| FY2017 | $1.75 | +6% |
| FY2016 | $1.65 | +143% |
| FY2015 | $0.68 | −41% |
| FY2014 | $1.16 | +15% |
| FY2013 | $1.01 | +16% |
| FY2012 | $0.87 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.65 | +1% | $6.07 | |
| Q1 FY26 | $1.42 | +6% | $6.05 | |
| Q4 FY25 | $1.37 | +6% | $5.97 | |
| Q3 FY25 | $1.63 | +9% | $5.89 | |
| Q2 FY25 | $1.63 | +19% | $5.76 | |
| Q1 FY25 | $1.34 | +2% | $5.50 | |
| Q4 FY24 | $1.29 | +13% | $5.47 | |
| Q3 FY24 | $1.50 | +16% | $5.32 | |
| Q2 FY24 | $1.37 | −6% | $5.11 | |
| Q1 FY24 | $1.31 | +10% | $5.19 | |
| Q4 FY23 | $1.14 | +15% | $5.07 | |
| Q3 FY23 | $1.29 | +14% | $4.92 |
Against its peers
Companies in Healthcare nearest Zoetis' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ZTSZoetis | $6.07 | +5% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| CNCCentene | −$10.44 | −358% a year |
| GEHCGE HealthCare Technologies | $4.36 | −11% a year |
| RMDResMed | $10.43 | +10% a year |
| RPRXRoyalty Pharma | $1.76 | −19% a year |
| BIIBBiogen | $5.65 | −46% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| DXCMDexCom | $2.52 | +76% a year |
| WSTWest Pharmaceutical Services | $7.81 | +17% a year |
| ILMNIllumina | $5.38 | −32% a year |
| Peer median | $5.51 |
Where Zoetis ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Zoetis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.